Chapter 1 : The History of Pneumococcal Disease

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

The History of Pneumococcal Disease, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap01-1.gif /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap01-2.gif


This chapter reviews some of the major events in the history of —events that have led to our modern understanding of the pathogenesis, diagnosis, treatment, and prevention of pneumococcal disease. Manifestations of primary infection involved the respiratory tract, including pneumonia, acute purulent tracheobronchitis, otitis media, and acute purulent sinusitis. Pneumococcal pneumonia was a driving force behind clinical and microbiologic research. Until the 1880s and 1890s, pneumonia had been regarded as a respiratory affliction rather than an infectious disease, with no specific therapy other than supportive care and various ineffectual potions and poultices. To provide serum treatment outside the academic medical centers, an ambitious new infrastructure of pneumonia control programs was developed with the intention of providing serum, usually at no cost, to treat the largest number of people possible. The general impression was that penicillin had conquered the pneumococcus: it eliminated the need for serotyping, for serum therapy, and for the further development of vaccines. The reality was that the very young and the very old continued to have high rates of mortality. Capsular type switching, originally observed in experiments with mice, has now been implicated in humans and may play an important role in the expansion of nonvaccine serotypes.

Citation: Gray B, Musher D. 2008. The History of Pneumococcal Disease, p 3-17. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch1

Key Concept Ranking

Pneumococcal Conjugate Vaccine
Infectious Diseases
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Part of Fig. 28, “Examination of sputum and cultures,” from Bullowa’s handbook (reference , p. 83). Reproduced with permission of Oxford University Press.

Citation: Gray B, Musher D. 2008. The History of Pneumococcal Disease, p 3-17. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Fever curve and treatment details from a patient, “Male, aged 25 years, 5th day single dose (120 cc.) (Processed Rabbit serum Pn. I) temperature normal in 6 hours.” (Bullowa’s Fig. 114, p. 348 [ ].) Note X-ray and culture results and tests for type I agglutinins in serum. Reproduced with permission of Oxford University Press.

Citation: Gray B, Musher D. 2008. The History of Pneumococcal Disease, p 3-17. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Mortality rates from pneumococcal pneumonia by age in the period before antibiotics (Boston 1929–1930), from Heffron’s monograph ( ); in the early antibiotic era (Brooklyn, 1952–1962), from Austrian and Gold ( ); and after well-established use (Chicago 1967–1970), from Mufson et al. ( ). (Figure by Daniel Musher.)

Citation: Gray B, Musher D. 2008. The History of Pneumococcal Disease, p 3-17. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Abraham, E. P.,, A. D. Gardner,, E. Chain,, N. G. Heatley,, C. M. Fletcher,, M. A. Jennings, and, H. W. Florey. 1941. Further observations on penicillin. Lancet ii:177189.
2. Anders, J. M. 1902. The serum treatment of pneumonia. JAMA 43:1780.
3. Armstrong, R. R. 1931. A swift and simple method for deciding pneumococcal “type.” BMJ i:214215.
4. Austrian, R. 1997. The enduring pneumococcus: unfinished business and opportunities for the future. Microb. Drug Resist. 3:111115.
5. Austrian, R. 1985. Life with the Pneumococcus: Notes from the Bedside, Laboratory, and Library. University of Pennsylvania Press, Philadelphia.
6. Austrian, R. 1975. Maxwell Finland Lecture. Random gleanings from a life with the pneumococcus. J. Infect. Dis. 131:474484.
7. Austrian, R. 1977. The Jeremiah Metzger Lecture. Of gold and pneumococci: a history of pneumococcal vaccines in South Africa. Trans. Am. Clin. Climatol. Assoc. 89:141161. [Reprint, Life with the Pneumococcus: Notes from the Bedside, Laboratory, and Library, p. 98118. University of Pennsylvania Press, Philadelphia, 1985.]
8. Austrian, R. 1957. Pneumococcal endocarditis, meningitis, and rupture of the aortic valve. Arch. Intern. Med. 99:539544.
9. Austrian, R. 2001. Pneumococcal otitis media and pneumococcal vaccines, a historical perspective. Vaccine 19:S71S77.
10. Austrian, R. 1981. Pneumococcus: the first one hundred years. Rev. Infect. Dis. 3:183189.
11. Austrian, R., and, J. Gold. 1964. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60:759776.
12. Avery, O. T.,, C. M. MacLeod, and, M. McCarty. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 79:137157.
13. Bezançon, F., and, V. Griffon. 1897. Pouvoir aggluninatif du sérum dan les infections expérimentales et humaines à pneumocoques. Part II. C. R. Soc. Biol. 49:579581.
14. Bickel, L. 1972. Rise Up to Life: a Biography of Howard Walter Florey, Who Gave Penicillin to the World. Charles Scribner’s Sons, New York, NY.
15. Binger, C. A. L. 1928. Anoxemia in pneumonia and its relief by oxygen inhalation. J. Clin. Investig. 6:203219.
16. Bullowa, J. G. M. 1937. The Management of the Pneumonias for Physicians and Medical Students. Oxford University Press, New York, NY.
17. Bunim, J. J. 1946. Pneumococcal arthritis treated with penicillin. Med. Clin. N. Am. 30:584596.
18. Byington, C. L.,, K. Korgenski,, J. S. Daly,, K. Ampofo,, A. Pavia, and, E. O. Mason. 2006. Impact of the pneumcoccal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25:250254.
19. Calvery, H. O., and, T. G. Klumpp. 1939. The toxicity for human beings of diethylene glycol with sulfanilamide. South Med. J. 32:10061007.
20. Casadevall, A., and, M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:16951707.
21. Cecil, R. L., and, N. Plummer. 1930. Pneumococcus type I pneumonia. A study of eleven hundred and sixty-one cases, with especial reference to specific therapy. JAMA 95:15471553.
22. Cecil, R. L., and, N. Plummer. 1932. Pneumococcus type II pneumonia. A clinical and bacteriologic study of one thousand cases, with especial reference to serum therapy. JAMA 98:779786.
23. Cecil, R. L.,, N. Plummer, and, M. McCall. 1936. Pneumococcus type II pneumonia. An analysis of 500 cases. Am. J. Med. Sci. 191:305319.
24. Charrin and Veillon. 1893. Peritonite à pneumococques sans pneumonie. C.R. Soc. Biol. 95:1057.
25. Claverys, J.-P.,, M. Prudhomme,, I. Mortier-Barrière, and, B. Martin. 2000. Adaptation to the environment: Streptococcus pneumoniae, a paradigm for recombination-mediated genetic plasticity. Mol. Microbiol. 35:251259.
26. Coffey, J. D. 1966. Otitis media in the practice of pediatrics. Bacteriological and clinical observations. Pediatrics 38:2532.
27. Cooper, G.,, C. Rosenstein,, A. Walter, and, L. Peizer. 1932. The further separation of types among the pneumococci hitherto included in group IV and the development of therapeutic antisera for these types. J. Infect. Dis. 55:531554.
28. Dawson, M. H., and, G. L. Hobby. 1944. The clinical use of penicillin: observations in one hundred cases. JAMA 124:611622.
29. Dochez, A. R., and, O. T. Avery. 1917. The elaboration of specific soluble substance by pneumococcus during growth. J. Exp. Med. 26:477493.
30. Dochez, A. R., and, O. T. Avery. 1917. Soluble substance of pneumococcus origin in the blood and urine during lobar pneumonia. J. Exp. Med. 26:477493.
31. Dochez, A. R., and, L. J. Gillespie. 1913. A biologic classification of pneumococci by means of immunity reactions. JAMA 61:727732.
32. Doll, R. 1998. Controlled trials: the 1948 watershed. Lancet 317:12171220.
33. Dowling, H. 1977. Fighting Infection: Conquests of the Twentieth Century. Harvard University Press, Cambridge, MA.
34. Dowling, H. 1973. The rise and fall of pneumonia-control programs. J. Infect. Dis. 127:201206.
35. Dowling, H.,, L. K. Sweet,, J. A. Robinson,, W. W. Zellers, and, H. L. Hirsch. 1949. The treatment of pneumococcic meningitis with massive doses of systemic penicillin. Am. J. Med. Sci. 217:149156.
36. Dubos, R. 1965. The evolution of medical microbiology, p. 1–19. In R. Dubos and, J. G. Hirsch (ed.), Bacterial and Mycotic Infections of Man. J. B. Lippincott Company, Philadelphia, PA.
37. Dubos, R. J. 1976. The Professor, the Institute, and DNA. Rockefeller University Press, New York, NY.
38. Dumoff-Stanley, E.,, H. Dowling, and, L. K. Sweet. 1946. The absorption into and distribution of penicillin in the cerebrospinal fluid. J. Clin. Investig. 25:8793.
39. Evans, G. M., and, W. F. Gaisford. 1938. Treatment of pneumonia with 2-(p-aminobenzenesulphonamido) pyradine. Lancet ii:1419.
40. Farrell, D. J.,, K. P. Klugman, and, M. Pichichero. 2007. Increased antimicrobial resistance among nonvaccine serotypes of streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 26:123128.
41. Felton, L. D. 1930. The concentration of anti-pneumococcus serum. JAMA 94:18931896.
42. Felton, L. D. 1924. A study of the isolation and concentration of the specific antibodies of antipneumococcus sera. Boston Med. Surg. J. 190:819825.
43. Felton, L. D., and, G. H. Bailey. 1926. The specific precipitates obtained from antipneumococcus serum and antibody solution by the soluble specific substance of pneumococci. J. Infect. Dis. 38:145164.
44. Finland, M. 1942. The present status of the higher types of antipneumococcus serums. JAMA 120:12941307.
45. Finland, M., and, T. D. Dublin. 1939. Pneumococci pneumonias complicating pregnancy and the puerperium. JAMA 112:10271032.
46. Finland, M.,, W. C. Spring, Jr., and, F. C. Lowell. 1940. Specific treatment of the pneumococci pneumonias: an analysis of the results of serum therapy and chemotherapy at the Boston City Hospital from July 1938 through June 1939. Ann. Intern. Med. 13:15761693.
47. Fraenkel, A. 1884. Ueber die genuine Pneumonie. Verh. Kongr. Inn. Med. 3:1731.
48. Francis, T., Jr. 1933. Value of skin test with type specific capsular polysaccharides in serum treatment of type I pneumococcus pneumonia. J. Exp. Med. 57:617631.
49. Freikin, D. R., and, K. P. Klugman. 2002. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35:547555.
50. Gamaléia, N. 1888. Sur l’étiologie de la pneumonie fibrineuse chez l’homme. Ann. Inst. Pasteur 2:440459.
51. Gay, F. P., and, H. T. Chickering. 1915. Concentration of the protective bodies in antipneumococcus serum by means of specific precipitation. Proc. Soc. Exper. Biol. Med. 12:115.
52. Gonzales-Juanatey, C.,, A. Testa,, J. May, and, M. A. Gonzales-Gay. 2006. Austrian syndrome: report of two new cases and literature review. Int. J. Cardiol. 108:273275.
53. Gonzalez, B. E.,, K. G. Hulten,, S. L. Kaplan, and, E. O. Mason, Jr. 2005. Clonality of Streptococcus pneumoniae serotype 1 isolates from pediatric patients in the United States. J. Clin. Microbiol. 42:28102812.
54. Goodner, K.,, F. L. Horsfall, and, R. J. Dubos. 1937. Type-specific antipneumococcic rabbit serum for therapeutic purposes. Production, processing, and standardization. J. Immunol. 33:279295.
55. Gram, C. 1884. Ueber die isolierte Färbung der Schizomyceten in Schnitt- und Trokenpräparaten. Fortschr. Med. 2:185189.
56. Griffith, F. 1928. The significance of pneumococcal types. J. Hyg. 27:113159.
57. Haldane, J. S. 1919. Symptoms. BMJ 2:6572.
58. Haldane, J. S. 1922. Respiration. Yale University Press, New Haven, CT.
59. Hansman, D. 1967. A resistant pneumococcus. Lancet ii:264265.
60. Hansman, D.,, H. Glasgow,, J. Sturt,, L. Devitt, and, R. Douglas. 1971. Increased resistance to penicillin of pneumococci isolated from man. N. Engl. J. Med. 284:175177.
61. Heffron, R. 1939. Pneumonia, with Special Reference to Pneumococcus Lobar Pneumonia. Commonwealth Fund, New York, NY. [Reprint, Harvard University Press, Boston, MA, 1979.]
62. Heidelberger, M., and, O. T. Avery. 1924. The soluble specific substance of pneumococcus. Second paper. J. Exp. Med. 40:301316.
63. Henriques Normark, B.,, M. Kalin,, A. Ortqvist,, T. Akerlund,, B. O. Liljequist,, J. Hedlund,, S. B. Svenson,, J. Zhou,, B. G. Spratt,, S. Normark, and, G. Kallenius. 2001. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J. Infect. Dis. 184:861869.
64. Hobby, G. 1985. Penicillin: Meeting the Challenge. Yale University Press, New Haven, CT.
65. Hróbjartsson, A.,, P. C. Gøtzche, and, C. Gluud. 1998. The controlled clinical trial turns 100 years: Fibiger’s trial of serum treatment of diphtheria. BMJ 317:12431245.
66. Issaeff, B. 1893. Contibution à l’étude de l’immunité acquise contre le pneumocoque. Ann. Inst. Pasteur 7:260279.
67. Jacobson, J. W. 1983. Gram’s discovery of his staining technique. J. Infect. 7:97101.
68. Keefer, C. S.,, F. G. Blake,, E. K. Marshall,, J. S. Lockwood, and, W. B. Wood. 1943. Penicillin treatment of infections. A report of 500 cases. JAMA 122:12171224.
69. King, H., and, H. B. Shumaker, Jr. 1952. Splenic studies. I. Susceptibility to infection after splenectomy performed in childhood. Am. J. Surg. 136:239242.
70. Klugman, K. P. 1990. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:171196.
71. Lacks, S. A. 2003. Rambling and scrambling in bacterial transformation: a historical and personal memoir. J. Bacteriol. 185:16.
72. Lesch, J. E. 1997. The discovery of M&B 693 (sulfapyridine), p. 101–119. In G. J. Higby and, E. C. Stroud (ed.), The Inside Story of Medicines: a Symposium. American Institute of the History of Pharmacy, Madison, WI.
73. Lister, F. S. 1917. Prophylactic inoculations of man against pneumococcal infections and more particularly against lobar pneumonia. Publ. S. Afr. Inst. Med. Res. 10:304322.
74. Long, S. S. 2005. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin. Infect. Dis. 41:3034.
75. Lord, F. T., and, R. Heffron. 1936. Lobar Pneumonia and Serum Therapy, with Special Reference to the Massachusetts Pneumonia Study. Commonwealth Fund, New York, NY.
76. Lund, E. 1960. Laboratory diagnosis of Pneumococcus infections. Bull. W. H. O. 23:513.
77. MacLeod, C. M.,, R. G. Hodges,, M. Heidelberger, and, W. G. Bernhard. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445465.
78. Markel, H. 1994. The genesis of the iron lung. Early attempts at administering artificial respiration to patients with poliomyelitis. Arch. Pediatr. Adolesc. Med. 148:11741180.
79. Marks, H. M. 1997. The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990. Cambridge University Press, New York, NY.
80. McCarty, M. 1986. The Transforming Principle: Discovering that Genes Are Made of DNA. W. W. Norton Company, New York, NY.
81. McKee, C. M., and, G. Rake. 1942. Activity of penicillin against strains of pneumococci resistant to sulfonamide drugs. Proc. Soc. Exp. Biol. Med. 51:275278.
82. Medical Research Council. 1934. Report of Therapeutic Trials Committee. The serum treatment of lobar pneumonia. BMJ i:241245.
83. Metchnikoff, E. 1891. Études sur l’immunité, 4e memoire. L’immunité de cobayes vaccinés contre le vibrio Metchnikowii. Ann. Inst. Pasteur 5:465478.
84. Moore, H. F., and, A. Chesney. 1918. A further study of ethylhydrocuprein (optochin) in the treatment of acute lobar pneumonia. Arch. Intern. Med. 21:659681.
85. Moore, H. F., and, A. Chesney. 1917. A study of ethylhydrocuprein (optochin) in the treatment of acute lobar pneumonia. Arch. Intern. Med. 19:611.
86. Morris, D. H., and, F. D. Bullock. 1919. The importance of the spleen in resistance to infection. Ann. Surg. 70:513521.
87. Mufson, M. A.,, D. M. Kruss,, R. E. Wasil, and, W. I. Metzger. 1974. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch. Intern. Med. 134:505510.
88. Musher, D. M. 2005. Streptococcus pneumoniae, p. 2392–2411. In G. L. Mandell,, J. E. Bennett, and, R. Dolin (ed.), Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 6th ed. Churchill Livingstone, New York, NY.
89. Musher, D. M.,, I. Alexandraki,, E. A. Graviss,, N. Yanbeiy,, A. Eid,, L. A. Inderias,, H. M. Phan, and, E. Solomon. 2000. Bacteremic and nonbacteremic pneumococcal pneumonia: a prospective study. Medicine 79:210221.
90. Musher, D. M.,, D. A. Watson, and, E. A. Dominguez. 1990. Pneumococcal vaccination: work to date and future prospects. Am. J. Med. Sci. 300:4552.
91. Nelson, J. D.,, M. D. Scheetz, et al. 1989. Proceedings of a workshop on vaccines for otitis media (organized and directed by C. D. Bluestone and J. O. Klein). Pediatr. Infect. Dis. J. 8:S6S97.
92. Nemir, R. L.,, E. T. Andrews, and, J. Vinograd. 1936. Pneumonia in infants and in children. A bacteriologic study with special reference to clinical significance. Am. J. Dis. Child. 51:12771295.
93. Neufeld, F. 1902. Ueber die Agglutination de Pneumokokken und über die Theorieen der Agglutination. Z. Hyg. Infektkrankh. 34:454464.
94. Nichols, H. J. 1917. The lobar pneumonia problem in the army from the viewpoint of the recent differentiation of types of pneumococci. Mil. Surg. 41:141161.
95. O’Brien, K. L., and, R. Dagan. 2003. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21:18151825.
96. Pahmer, M. 1940. Pneumococcal peritonitis in nephrotic and nonnephrotic children: a comparative clinical and pathologic study with a brief review of the literature. J. Pediatr. 17:90106.
97. Park, W. H.,, J. G. M. Bullowa, and, M. B. Rosenbluth. 1928. The treatment of lobar pneumonia with refined specific antibacterial serum. JAMA 91:15031508.
98. Pasteur, L.,, Chamberland, and, E. Roux. 1881. Sur une maladie nouvelle, provoquée par la salive d’un enfant mort de la rage. C. R. Acad. Sci. 92:159165.
99. Podolsky, S. H. 2006. Pneumonia before Antibiotics. Johns Hopkins University Press, Baltimore, MD.
100. Porat, N.,, A. Arguedas,, B. G. Spratt,, R. Trefler,, E. Brilla,, C. Loaiza,, D. Godoy,, N. Bilek, and, R. Dagan. 2004. Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J. Infect. Dis. 190:21542161.
101. Prudhomme, M.,, L. Attaiech,, G. Sanches,, B. Martin, and, J.-P. Claverys. 2006. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science 313:8992.
102. Raia, A.,, N. Plummer, and, S. Shultz. 1931. New types of pneumococci in the pneumonias of children. Am. J. Dis. Child. 42:5768.
103. Reimann, H. A. 1938. The Pneumonias, 1st ed. W. B. Saunders Company, Philadelphia, PA.
104. Reimann, H. A. 1954. Pneumonia, 2nd ed. Charles C Thomas, Springfield, IL.
105. Reimann, H. A. 1971. The Pneumonias, 3rd ed. Warren H. Green, Inc., St. Louis, MO.
106. Robinson, M. G., and, R. J. Watson. 1966. Pneumococcal meningitis in sickle-cell anemia. N. Engl. J. Med. 274:10061008.
107. Rogers, E. S. 1937. The New York State program for the control of pneumococcus pneumonia. Am. J. Public Health 27:133141.
108. Sabin, A. B. 1930. The microscopic agglutination test in pneumonia. Its application to rapid typing and control of serum therapy. J. Infect. Dis. 46:469484.
109. Schiemann, O., and, W. Casper. 1927. Sind die spezifisch präcipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z. Hyg. Infektkrankh. 108:220257.
110. Schmidt, L. H., and, C. L. Sesler. 1943. Development of resistance to penicillin by pneumococci. Proc. Soc. Exp. Biol. Med. 52:353357.
111. Shope, T. C., and, P. G. Quie. 1968. D. pneumoniae. Increased resistance to oxacillin and cloxacillin. Minn. Med. 51:3738.
112. Singleton, R. J.,, T. Hennessy,, L. R. Bulkow,, L. L. Hammitt,, T. Zulz,, D. A. Hurlburt,, J. C. Butler,, K. Rudolph, and, A. Parkinson. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:17841792.
113. Smillie, W. G., and, F. S. Leeder. 1934. Epidemiology of lobar pneumonia. Am. J. Pub. Health 24:129138.
114. Smillie, W. G.,, G. H. Warnock, and, H. J. White. 1938. A study of a type I pneumococcus epidemic at the state hospital at Worcester, Mass. Am. J. Public Health 28:293302.
115. Sternberg, G. M. 1881. A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. Bull. Natl. Board Health 2:781803.
116. Stryker, L. M. 1916. Variation in the pneumococcus induced by growth in immune serum. J. Exp. Med. 24:4968.
117. Tilghman, R. C., and, M. Finland. 1937. Clinical significance of bacteremia in pneumococcic pneumonia. Arch. Intern. Med. 59:602619.
118. Tillett, W. S.,, M. J. Cambier, and, W. H., J. Harris. 1943. Sulfonamide-fast pneumococci: a clinical report of two cases of pneumonia together with experimental studies on the effectiveness of penicillin and tyrothricin against sulfonamide-resistant strains. J. Clin. Investig. 22:249255.
119. Tillett, W. S.,, J. E. McCormick, and, M. J. Cambier. 1945. The use of penicillin in the local treatment of pneumococcal empyema. J. Clin. Investig. 22:595610.
120. Tillett, W. S.,, J. E. McCormick, and, M. J. Cambrier. 1945. The treatment of lobar pneumonia with penicillin. J. Clin. Investig. 24:589594.
121. Tomasz, A. 1999. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am. J. Med. 107(1A):55S62S.
122. Trask, J. D.,, C. J. O’Donovan, and, D. M. Moore. 1930. Studies of pneumonia in children. I. Mortality, blood cultures, and humoral antibodies in pneumococcus pneumonia. J. Clin. Investig. 8:623651.
123. Wadsworth, A. K. 1924. Review of recently published reports on the serum treatment of type I pneumonia, together with a report of 445 additional cases. Am. J. Hyg. 4:119133.
124. Ward, H. K., and, J. F. Enders. 1933. An analysis of the opsonic and tropic action of normal and immune sera based on experiments with the pneumococcus. J. Exp. Med. 57:527547.
125. Watson, D. A.,, D. M. Musher,, J. W. Jacobson, and, J. Verhoef. 1993. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin. Infect. Dis. 17:913924.
126. Weichselbaum, A. 1886. Ueber die Aetiologie der acuten Lungen- und Rippenfallentzündungen. Med. Jahrb. Ser. 3 1:485554.
127. White, B. 1938. The Biology of the Pneumococcus: the Bacteriological, Biochemical and Immunological Characters and Activities of Diplococcus pneumoniae, Commonwealth Fund, New York, NY. [Reprint, Harvard University Press, Boston, MA, 1979.]
128. Wood, W. B., Jr. 1940. The control of the dosage of antiserum in the treatment of pneumococcal pneumonia. II. The clinical application of the Francis skin test. J. Clin. Investig. 19:105121.
129. Wright, A. E., and, S. R. Douglas. 1904. Further observations on the role of the blood fluids in connection with phagocytosis. Proc. R. Soc. Lond. 73:128142.
130. Wright, F. H., and, J. A. Washington. 1954. Pneumonia, p. 533–542. In I. E., Holt and, R. McIntosh (ed.), Holt’s Pediatrics, 12th ed. Appleton-Century-Crofts, New York, NY.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error